Eli Lilly and Company has taken the lead in in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant potential to improve glycemic control and reduce the risk of cardiovascular disease. The complex manufacturing process of tirzepatide involves a ser